MedPath

A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases

Phase 3
Not yet recruiting
Conditions
Interstitial Lung Diseases
Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases
Interventions
Drug: Placebo matching nerandomilast
Registration Number
NCT06806592
Lead Sponsor
Boehringer Ingelheim
Brief Summary

Adults 18 years of age and older or above legal age with lung fibrosis related to systemic autoimmune rheumatic disease can participate in this study. People can only take part if they show no improvement in lung function after standard treatment with immunosuppressant medicine. The main purpose of this study is to find out how a medicine called nerandomilast affects the lungs in people with systemic autoimmune rheumatic disease.

Participants are put into 2 groups randomly, which means by chance. One group takes nerandomilast tablets and the other group takes placebo tablets. Placebo tablets look like nerandomilast tablets but do not contain any medicine. Participants take a tablet 2 times a day for 26 weeks. Participants continue immunosuppressant treatment for their underlying rheumatic disease.

Participants are in the study for about 7.5 months. During this time, they visit the study site 8 times. At study visits, participants have lung function tests. At select visits, chest imaging is performed. Participants fill in questionnaires about their symptoms and quality of life. The results between the 2 groups are compared to see whether the treatment works. The doctors also regularly check participants' health and take note of any unwanted effects.

Detailed Description

Not available

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
400
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
NerandomilastNerandomilastParticipants with SARD-ILDs will receive nerandomilast.
PlaceboPlacebo matching nerandomilastParticipants with SARD-ILDs will receive placebo.
Primary Outcome Measures
NameTimeMethod
Absolute change from baseline in quantitative interstitial lung disease (QILD) score [%] at Week 26.At baseline and at Week 26

QILD will be assessed via quantitative high-resolution computed tomography (qHRCT). QILD are quantitative measures of different radiological patterns associated with lung fibrosis. QLF is a measure of reticulation with architectural distortion. QGGO is a measure of ground glass opacities (i.e. hazy or cloudy areas) within the lung. QHC is a measure of HC within the lung. QILD is the sum of QLF, QGGO, and QHC.

Quantification of HRCT scans will be performed centrally via a machine learning algorithm. QILD \[%\] is the QILD volume \[mL\] as a percent of the total lung volume.

A higher QILD percentage or volume indicates a higher extent of disease.

Secondary Outcome Measures
NameTimeMethod
Absolute change from baseline in quantitative lung fibrosis (QLF) score [%] at Week 26At baseline and at Week 26

QLF will be assessed via qHRCT. QLF are quantitative measures of different radiological patterns associated with lung fibrosis. QLF is a measure of reticulation with architectural distortion.

Quantification of HRCT scans will be performed centrally via a machine learning algorithm. QILD \[%\] is the QILD volume \[mL\] as a percent of the total lung volume.

A higher QILD percentage or volume indicates a higher extent of disease.

Absolute change from baseline in quantitative ground glass opacity (QGGO) score [%] at Week 26At baseline and at Week 26

QGGO will be assessed via qHRCT. QGGO are quantitative measures of different radiological patterns associated with lung fibrosis. QGGO is a measure of ground glass opacities (i.e. hazy or cloudy areas) within the lung.

Quantification of HRCT scans will be performed centrally via a machine learning algorithm.

A higher QGGO percentage or volume indicates a higher extent of disease.

Absolute change from baseline in forced vital capacity (FVC) [mL] at Week 26At baseline and at Week 26

FVC will be assessed using standardised spirometry equipment which will be provided centrally with supplies of precalibrated disposable flow sensors. Spirometry will be conducted with the participant in a seated position. It is preferable that the same trained individual (i.e. PFT specialist or pulmonologist) performs the PFTs for a given participant. The best of 3 efforts will be defined as the highest FVC obtained on any of three blows meeting the 2019 American Thoracic Society/European Respiratory Society (ATS/ERS) criteria (with a maximum of eight attempts). Predicted normal values will be calculated according to global lung function initiative (GLI).

Absolute change from baseline in living with pulmonary fibrosis (L-PF) Symptoms Dyspnoea domain score at Week 26At baseline and at Week 26

L-PF is a self-administered 44 item patient reported outcome measure (PROM) with 2 modules: Symptoms (23 items) and Impacts (21 items). The Symptom module assesses 3 domains (dyspnoea, cough, and fatigue) in the past 24 h. The Impact questionnaire assesses impact related to dyspnoea, cough, energy, and global within the last week. Both modules have a 5-point Likert scale with varying response options. For the Symptoms module, a total Symptom score as well as Symptoms domain scores (dyspnoea, cough, and fatigue) are generated. The Impacts module yields a single Impacts score. Scoring is performed as a summary score, the mean of the dimension ratings multiplied by 100. The L-PF symptom module domain and total scores as well as the L-PF impact module total score range from 0 to 100, with higher scores indicating a greater impairment.

There are 5 additional questions pertaining to oxygen use at the end of the Symptoms module to serve interpretation of the L-PF scores.

Absolute change from baseline in living with pulmonary fibrosis (L-PF) Symptoms Cough domain score at Week 26At baseline and at Week 26

L-PF is a self-administered 44 item patient reported outcome measure (PROM) with 2 modules: Symptoms (23 items) and Impacts (21 items). The Symptom module assesses 3 domains (dyspnoea, cough, and fatigue) in the past 24 h. The Impact questionnaire assesses impact related to dyspnoea, cough, energy, and global within the last week. Both modules have a 5-point Likert scale with varying response options. For the Symptoms module, a total Symptom score as well as Symptoms domain scores (dyspnoea, cough, and fatigue) are generated. The Impacts module yields a single Impacts score. Scoring is performed as a summary score, the mean of the dimension ratings multiplied by 100. The L-PF symptom module domain and total scores as well as the L-PF impact module total score range from 0 to 100, with higher scores indicating a greater impairment.

There are 5 additional questions pertaining to oxygen use at the end of the Symptoms module to serve interpretation of the L-PF scores.

Occurrence of infection-related adverse events (AEs) from baseline to Week 26At baseline and at Week 26

Trial Locations

Locations (139)

HOP Sud

🇫🇷

Rennes, France

HOP Civil

🇫🇷

Strasbourg, France

HOP Rangueil

🇫🇷

Toulouse, France

Charite Universitätsmedizin Berlin KöR

🇩🇪

Berlin, Germany

Immanuel-Krankenhaus GmbH

🇩🇪

Berlin, Germany

Universitätsklinikum Bonn AöR

🇩🇪

Bonn, Germany

Kitasato University Hospital

🇯🇵

Kanagawa, Sagamihara, Japan

University of Alabama at Birmingham

🇺🇸

Birmingham, Alabama, United States

University of California Los Angeles

🇺🇸

Los Angeles, California, United States

National Jewish Health

🇺🇸

Denver, Colorado, United States

Yale University School of Medicine

🇺🇸

New Haven, Connecticut, United States

Miami VA Healthcare System

🇺🇸

Miami, Florida, United States

Augusta University

🇺🇸

Augusta, Georgia, United States

Northwestern University

🇺🇸

Chicago, Illinois, United States

Evanston Hospital

🇺🇸

Evanston, Illinois, United States

University of Kansas Medical Center

🇺🇸

Kansas City, Kansas, United States

LSU Health Sciences Center

🇺🇸

New Orleans, Louisiana, United States

Massachusetts General Hospital

🇺🇸

Boston, Massachusetts, United States

Brigham and Women's Hospital

🇺🇸

Boston, Massachusetts, United States

University of Minnesota

🇺🇸

Minneapolis, Minnesota, United States

University of Nebraska Medical Center

🇺🇸

Omaha, Nebraska, United States

NYU Langone Health

🇺🇸

New York, New York, United States

Columbia University Medical Center-New York Presbyterian Hospital

🇺🇸

New York, New York, United States

Onsite Clinical Solutions

🇺🇸

Salisbury, North Carolina, United States

Cleveland Clinic

🇺🇸

Cleveland, Ohio, United States

Temple Lung Center

🇺🇸

Philadelphia, Pennsylvania, United States

University of Pittsburgh Medical Center

🇺🇸

Pittsburgh, Pennsylvania, United States

The University of Texas Health Science Center at Houston

🇺🇸

Houston, Texas, United States

University of Utah Health Sciences Center

🇺🇸

Salt Lake City, Utah, United States

Rheumatology and Pulmonary Clinic

🇺🇸

Beckley, West Virginia, United States

University of Wisconsin

🇺🇸

Madison, Wisconsin, United States

Royal Prince Alfred Hospital

🇦🇺

Camperdown, Sydney, New South Wales, Australia

St Vincent's Hospital Sydney

🇦🇺

Darlinghurst, New South Wales, Australia

The Prince Charles Hospital

🇦🇺

Chermside, Queensland, Australia

Austin Hospital

🇦🇺

Heidelberg, Victoria, Australia

Fiona Stanley Hospital

🇦🇺

Murdoch, Western Australia, Australia

Krems University Hospital

🇦🇹

Krems, Austria

Klinikum Wels - Grieskirchen GmbH

🇦🇹

Wels, Austria

AKH - Medical University of Vienna

🇦🇹

Vienna, Austria

HOP d'Angers

🇫🇷

Angers, France

Beijing Chao-Yang Hospital

🇨🇳

Beijing, China

China-Japan Friendship Hospital

🇨🇳

Beijing, China

Peking Union Medical College Hospital

🇨🇳

Beijing, China

West China Hospital

🇨🇳

Chengdu, China

People's Hospital of Sichuan Province

🇨🇳

Chengdu, China

Guangdong Provincial People's Hospital

🇨🇳

Guangzhou, China

The First Affiliated Hospital, Zhejiang University

🇨🇳

Hangzhou, China

The First Affiliated Hospital of Henan University of Science and Technology

🇨🇳

Luoyang, China

The Second Affiliated Hospital Zhejiang University School of Medicine

🇨🇳

Hangzhou, China

University Hospital_Macau University of Science and Technology

🇨🇳

Macau, China

The First Affiliated Hospital of Nanchang University

🇨🇳

Nanchang, China

Huashan Hospital, Fudan University

🇨🇳

Shanghai, China

HOP Pellegrin

🇫🇷

Bordeaux, France

Tianjin Medical University General Hospital

🇨🇳

Tianjin, China

Tongji Hospital Affiliated Tongji Medical College Huazhong University of S & T

🇨🇳

Wuhan, China

First Affiliated Hospital of Xiamen University

🇨🇳

Xiamen, China

Zhuzhou Central Hospital

🇨🇳

Zhuzhou, China

Wuhan Union Hospital

🇨🇳

Wuhan, China

HOP Claude Huriez

🇫🇷

Lille, France

HOP Cochin

🇫🇷

Paris, France

HOP Bichat

🇫🇷

Paris, France

Städtisches Klinikum Braunschweig gGmbH

🇩🇪

Braunschweig, Germany

Gesundheit Nord gGmbH | Klinikverbund Bremen

🇩🇪

Bremen, Germany

Technische Universität Dresden

🇩🇪

Dresden, Germany

Universitätsklinikum Düsseldorf

🇩🇪

Düsseldorf, Germany

Universitätsklinikum Erlangen

🇩🇪

Erlangen, Germany

Universitätsklinikum Freiburg

🇩🇪

Freiburg, Germany

Helios Fachklinik Vogelsang-Gommern GmbH

🇩🇪

Gommern, Germany

Medizinische Hochschule Hannover

🇩🇪

Hannover, Germany

St. Elisabeth Gruppe GmbH Katholische Kliniken Rhein-Ruhr

🇩🇪

Herne, Germany

medius Kliniken gGmbH

🇩🇪

Kirchheim unter Teck, Germany

Klinikum Konstanz

🇩🇪

Konstanz, Germany

Krankenhaus Porz am Rhein gGmbH

🇩🇪

Köln, Germany

Universitätsklinikum Schleswig-Holstein, Campus Lübeck

🇩🇪

Lübeck, Germany

Johannes Wesling Klinikum Minden

🇩🇪

Minden, Germany

Klinikum der Universität München AÖR

🇩🇪

München, Germany

Krankenhaus Barmherzige Brüder Regensburg

🇩🇪

Regensburg, Germany

ASST degli Spedali Civili di Brescia

🇮🇹

Brescia, Italy

A. O. Universitaria Careggi

🇮🇹

Frienze, Italy

Fondazione IRCCS Ca'Granda-Ospedale Maggiore Policlinico

🇮🇹

Milano, Italy

IRCCS San Raffaele

🇮🇹

Milano, Italy

Azienda Ospedaliera Policlinico di Modena

🇮🇹

Modena, Italy

Università degli Studi Padova

🇮🇹

Padova, Italy

Fondazione IRCCS Policlinico S. Matteo

🇮🇹

Pavia, Italy

Fujita Health University Hospital

🇯🇵

Aichi, Toyoake, Japan

Hospital of the University of Occupational and Environmental Health

🇯🇵

Fukuoka, Kitakyushu, Japan

Hiroshima University Hospital

🇯🇵

Hiroshima, Hiroshima, Japan

Sapporo Medical University Hospital

🇯🇵

Hokkaido, Sapporo, Japan

Hokkaido University Hospital

🇯🇵

Hokkaido, Sapporo, Japan

Kagawa University Hospital

🇯🇵

Kagawa, Kita-gun, Japan

St. Marianna University Hospital

🇯🇵

Kanagawa, Kawasaki, Japan

Kyoto University Hospital

🇯🇵

Kyoto, Kyoto, Japan

Nagasaki University Hospital

🇯🇵

Nagasaki, Nagasaki, Japan

Osaka Medical and Pharmaceutical University Hospital

🇯🇵

Osaka, Takatsuki, Japan

Saitama Medical University Hospital

🇯🇵

Saitama, Iruma-gun, Japan

Juntendo University Hospital

🇯🇵

Tokyo, Bunkyo-Ku, Japan

Nippon Medical School Hospital

🇯🇵

Tokyo, Bunkyo-ku, Japan

Keio University Hospital

🇯🇵

Tokyo, Shinjuku-ku, Japan

Seoul National University Bundang Hospital

🇰🇷

Seongnam, Korea, Republic of

Kyung Hee University Hospital

🇰🇷

Seoul, Korea, Republic of

Seoul National University Hospital

🇰🇷

Seoul, Korea, Republic of

Soonchunhyang University Hospital Seoul

🇰🇷

Seoul, Korea, Republic of

Investigacion y Biomedicina de Chihuahua S.C.

🇲🇽

Chihuahua, Mexico

Soltmed Smo

🇲🇽

Ciudad de Mexico, Mexico

CITER Centro de Investigación y Tratamiento de las Enfermedades Reumaticas SA de CV

🇲🇽

Ciudad de Mexico, Mexico

Centro Integral en Reumatologia, SA. de CV.

🇲🇽

Guadalajara, Mexico

Medical Care & Research SA de CV

🇲🇽

Merida, Mexico

Inst Nac de Ciencias Medicas y Nutricion Salvador Zubiran

🇲🇽

Mexico City, Mexico

Hospital Universitario Dr Jose Eleuterio Gonzalez

🇲🇽

Monterrey, Mexico

Zuyderland Medisch Centrum

🇳🇱

Heerlen, Netherlands

St. Antonius ziekenhuis, locatie Nieuwegein

🇳🇱

Nieuwegein, Netherlands

Erasmus Medisch Centrum-ROTTERDAM-50697

🇳🇱

Rotterdam, Netherlands

Akershus Universitetssykehus HF

🇳🇴

Nordbyhagen, Norway

Sykehuset Telemark HF, Avd. Skien

🇳🇴

Skien, Norway

Hospital Santa Creu i Sant Pau

🇪🇸

Barcelona, Spain

Hospital Vall d'Hebron

🇪🇸

Barcelona, Spain

Hospital de Basurto

🇪🇸

Bilbao, Spain

Hospital Universitario Reina Sofía-Córdoba-40500

🇪🇸

Córdoba, Spain

Hospital de Bellvitge

🇪🇸

L'Hospitalet de Llobregat, Spain

Hospital Ramón y Cajal

🇪🇸

Madrid, Spain

Fundación Jiménez Díaz

🇪🇸

Madrid, Spain

Hospital Universitario 12 de Octubre

🇪🇸

Madrid, Spain

Hospital Clínico de Santiago

🇪🇸

Santiago de Compostela, Spain

Hospital Virgen del Rocío

🇪🇸

Sevilla, Spain

Hospital Dr. Peset

🇪🇸

Valencia, Spain

Complejo Hospitalario Universitario de Vigo

🇪🇸

Vigo, Spain

Cantonal Hospital of Aarau

🇨🇭

Aarau, Switzerland

University Hospital Basel

🇨🇭

Basel, Switzerland

Hopitaux Universitaires de Geneve (HUG)

🇨🇭

Geneve, Switzerland

Neuchatel Hospital Network

🇨🇭

Neuchatel, Switzerland

Kantonsspital St.Gallen

🇨🇭

St. Gallen, Switzerland

University Hospital Zurich

🇨🇭

Zürich, Switzerland

Antrim Area Hospital

🇬🇧

Antrim, United Kingdom

Heartlands Hospital

🇬🇧

Birmingham, United Kingdom

Altnagelvin Area Hospital

🇬🇧

Londonderry, United Kingdom

St George's Hospital-London-26733

🇬🇧

London, United Kingdom

Royal Brompton Hospital

🇬🇧

London, United Kingdom

Royal Hallamshire Hospital

🇬🇧

Sheffield, United Kingdom

Royal Cornwall Hospital

🇬🇧

Truro, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath